Carlos Rodríguez-Nogales

Carlos Rodríguez-Nogales

Auto-generated profile, based on publicly available information

Carlos Rodríguez-Nogales

School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
BRBenjamin Rossier
Benjamin Rossier
OJOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann
CRCarlos Rodríguez-Nogales
Carlos Rodríguez-Nogales
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.

16 October 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Luca MoriciLuca Morici
Luca Morici
EAEric Allémann
Eric Allémann
CRCarlos Rodríguez-Nogales
Carlos Rodríguez-Nogales
Olivier JordanOlivier Jordan
Olivier Jordan
Osteoarthritis (OA) is a joint disease common worldwide. Currently, no disease-modifying osteoarthritis drugs (DMOADs) have successfully passed clinical trials, often due to a lack of cartilage penetration. Thus, targeting the extracellular matrix (ECM) is a major priority. The design of cartilage-targeting drug delivery systems (DDSs) for intra-articular administration requires consideration of the physicochemical properties of articular cartilage, such as its porosity and negative fixed charge. Various positively charged biomaterials such as polyaminoacids, proteins, polymers, and lipids can be used as DDSs to enhance cartilage penetration. Cationic nanocarriers interact electrostatically with anionic glycosaminoglycans of the ECM, ensuring passive cartilage-targeting penetration and prolonged retention. Active targeting strategies involve DDSs surface decoration using antibodies or peptides with a strong affinity for collagen II and chondrocytes in the cartilage. This review presents all the relevant bio-physicochemical properties of healthy and OA cartilages, as well as state-of-the-art intra-articular cartilage-targeted DDSs, intending to better understand the recent advances in the application of cartilage-targeting delivery systems for OA therapy.

1 February 2016 in Maturitas
Verified
Journal Article
Closed access
CRC. Rodríguez-Nogales
C. Rodríguez-Nogales
Elisa Garbayo AtienzaElisa Garbayo Atienza
Elisa Garbayo Atienza
MCMar Carmona-Abellan
Mar Carmona-Abellan
Rosario LuquinRosario Luquin
Rosario Luquin
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto

30 December 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Luca MoriciLuca Morici
Luca Morici
PGPaula Gonzalez-Fernandez
Paula Gonzalez-Fernandez
SJSébastien Jenni
Sébastien Jenni
APAlexandre Porcello
Alexandre Porcello
EAEric Allémann
Eric Allémann
CRCarlos Rodríguez-Nogales
Carlos Rodríguez-Nogales
Osteoarthritis is the most common chronic joint disease and a major health care concern due to the lack of efficient treatments. This is mainly related to the local and degenerative nature of this disease. Kartogenin was recently reported as a disease-modifying osteoarthritis drug that promotes cartilage repair, but its therapeutic effect is impeded by its very low solubility. Therefore, we designed a unique nanocrystal-chitosan particle intra-articular delivery system for osteoarthritis treatment that merges the following formulation techniques: nanosize reduction of a drug by wet milling and spray drying. The intermediate formulation (kartogenin nanocrystals) increased the solubility and dissolution rates of kartogenin. The final drug delivery system consisted of an easily resuspendable and ready-to-use microsphere powder for intra-articular injection. Positively charged chitosan microspheres with a median size of approximately 10 µm acted as a mothership drug delivery system for kartogenin nanocrystals in a simulated intra-articular injection. The microspheres showed suitable stability and a controlled release profile in synovial fluid and were nontoxic in human synoviocytes. The cartilage retention skills of the microspheres were also explored ex vivo using cartilage. This drug delivery system shows promise for advancement to preclinical stages in osteoarthritis therapy and scale-up production.

31 May 2025 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
Luca MoriciLuca Morici
Luca Morici
Olivier JordanOlivier Jordan
Olivier Jordan
EAEric Allémann
Eric Allémann
CRCarlos Rodríguez-Nogales
Carlos Rodríguez-Nogales
More than 500 million people worldwide suffer from arthritis, experiencing daily pain and inflammation. Current treatments for osteoarthritis (OA) and rheumatoid arthritis (RA) are palliative, offering only symptom relief. No disease-modifying OA drugs (DMOADs) capable of restoring joint functionality and regenerating the cartilage matrix have yet been approved by the FDA or EMA. This review highlights recent advances in nanocrystals for arthritis drug delivery, including conventional nanosuspensions and novel transdermal microneedles. Special attention is given to intra-articular DMOADs formulated as nanocrystal-in-microparticles, designed to extend drug release over months. Papers and reviews with the mentioned contents and published over the last 5 years were included in the review process. New DMOADs and disease-modifying antirheumatic drugs (DMARDs) are often poorly water-soluble, limiting their clinical progress. The versatility of nanocrystals and nanosuspensions offers a potential advantage over other types of nanoparticles, as they can be adapted to various delivery systems, administration routes, and types of arthritis. Due to the avascular nature of cartilage, exploring the intra-articular route for OA management is essential. Implementing cartilage-targeted strategies or using stimuli-responsive hydrogels can further enhance their therapeutic potential.

1 November 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
CRC. Rodríguez-Nogales
C. Rodríguez-Nogales
Elisa Garbayo AtienzaElisa Garbayo Atienza
Elisa Garbayo Atienza
IMIván Martínez-Valbuena
Iván Martínez-Valbuena
VSV. Sebastián
V. Sebastián
Rosario LuquinRosario Luquin
Rosario Luquin
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto
Polo like kinase 2 (PLK2), a serine/threonine serum inducible kinase, has been proposed to be the major factor responsible for phosphorylating alpha-synuclein (α-syn) at Serine-129 (Ser-129) in Parkinson's disease (PD). A suitable strategy to gain insights into PLK2's biological effects might be to increase PLK2 intracellular levels with the aim of reproducing the slow progressive neuronal changes that occur in PD. The goal of this study was to develop and characterize a novel drug delivery system (DDS) for PLK2 cytosolic delivery using Total recirculating one machine system (TROMS), a technique capable of encapsulating fragile molecules while maintaining their native properties. A protocol for nanoparticle (NP) preparation using TROMS was set up. NPs showed a mean diameter of 257±15.61nm and zeta potential of -16±2mV, suitable for cell internalization. TEM and SEM images showed individual, spherical, dispersed NPs. The drug entrapment efficacy was 61.86±3.9%. PLK2-NPs were able to enter SH-SY5Y cells and phosphorylate α-syn at Ser-129, demonstrating that the enzyme retained its activity after the NP manufacturing process. This is the first study to develop a DDS for continuous intracellular delivery of PLK2. These promising results indicate that this novel nanotechnology approach could be used to elucidate the biological effects of PLK2 on dopaminergic neurons.